O-7111 Oxaliplatin, >99%

Synonyms : [RP 54780]

Related Terms : [Eloxatin] [Eloxatine] [Elplat] [Foloxatine] [Oxalatoplatin] [Oxalatoplatinum] [Transplatin]

  • Size
  • US $
  • £
  • ¥
  • 300 mg
  • 82
  • 76
  • 64
  • 13,000
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 122
  • 113
  • 95
  • 19,300
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 191
  • 177
  • 150
  • 30,200
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 334
  • 310
  • 262
  • 52,800
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 625
  • 581
  • 491
  • 98,800
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 397.29
  • C8H14N2O4Pt
  • [61825-94-3]
  • M.I. 14: 6912

Storage: Store at or below -20 ºC. Solubility: Soluble in water at 4 mg/mL and DMSO at 20 mg/mL; very slightly soluble in methanol; insoluble in ethanol. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 210 labs worldwide have purchased Oxaliplatin from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • Oxaliplatin is a a third-generation, diaminocyclohexane-containing platinum anti-cancer drug. It is typically used in combination with fluorouracil (5-FU) and leucovorin, known as FOLFOX, for the treatment of colorectal cancer. The leucovorin-modulated single-agent 5-FU regimens achieved a median overall survival of 15 months or less. Combination regimens of FOLFOX consistently lead to median survivals in the 15 to 20-month range. Goldberg, R.M. "Therapy for Metastatic Colorectal Cancer." The Oncologist 11: 981-987 (2006).
  • Oxaliplatin has different antitumor spectrum, mechanisms of action, and resistance from the other platinum-containing compounds, notably cisplatin. Raymond, E., et al. "Cellular and molecular pharmacology of oxaliplatin." Mol. Cancer Ther. 1: 227-235 (2002).
  • The anticancer activity and the antitumor specificity of oxaliplatin mainly depend on human organic cation transporters (OCT) 1 and OCT2. Zhang, S., et al. "Organic cation transporters are determinants of oxaliplatin cytotoxicity." Cancer Res. 66: 8847-8857 (2006).
  • The oxaliplatin cytotoxicity depends on MKK7/JNK, while SEK1 might be involved in hypoxic resistance to oxaliplatin. Vasilevskaya, I.A., et al. "Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin." Mol. Pharmacol. 74: 246-254 (2008).
  • Oxaliplatin is the active ingredient in the drug product sold under numerous trade names, such as those listed near the top of this page as "Related Terms". This drug has been approved in at least one country for use in patients with colorectal cancer. NOTE: THE OXALIPLATIN SOLD BY LC LABORATORIES FOR RESEARCH IS NOT ANY OF THE OXALIPLATIN-CONTAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES, AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.